Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05872139 · ClinicalTrials.gov registry record · NA

Role of Mitochondrial-derived Oxidative Stress to Promote Vascular Endothelial Dysfunction in Non-exercisers With Aging

A NA study of Aging and Endothelial Dysfunction, sponsored by Ball State University.

Completed
Registry status
NA
Development phase
23
Enrollment target
1
Study location

NCT05872139: Completed NA study of Aging and Endothelial Dysfunction, sponsored by Ball State University.

NCT05872139 is a NA study of Aging and Endothelial Dysfunction that has completed, run by Ball State University. The registered enrollment target is 23 participants, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05872139, a NA study of Aging and Endothelial Dysfunction, has completed, sponsored by Ball State University.

COMPLETED
Registry status
NA
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

The primary goal of this intervention is to determine the efficacy of acute mitochondrial-specific antioxidants to improve vascular endothelial function in middle-aged and older (≥45 y) adults who do no perform regular aerobic exercise. In a double-blind, randomized, placebo-controlled crossover design participants with receive both MitoQ and placebo arm of the study. Primary endpoints will include vascular endothelial function assessed by brachial artery flow-mediated dilation and cardiac function assessed via pulse wave analysis. Secondary endpoints will include measures of aortic stiffness assessed by carotid-femoral pulse wave velocity and carotid artery stiffness (e.g. β-stiffness) and elasticity (carotid compliance, distensibility, and Youngs elastic modulus) from ultrasonography.

Primary Outcome

Brachial artery flow-mediated dilation (% \[relative\] and mm \[absolute\])

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Mitoquinone Mesylate

Study Locations (1)

Indiana

  • Ball State University - Muncie

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2022-09-23
Est. Completion 2023-05-01
Phase NA
Ball State University

12 total trials

What the finished NCT05872139 record still lists

NCT05872139 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (99% lower).

The record links to 4 conditions, with Aging appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05872139 reports a single indexed study location in Indiana.

Frequently Asked Questions

What is clinical trial NCT05872139 about?

NCT05872139 is a clinical study titled "Role of Mitochondrial-derived Oxidative Stress to Promote Vascular Endothelial Dysfunction in Non-exercisers With Aging". The primary goal of this intervention is to determine the efficacy of acute mitochondrial-specific antioxidants to improve vascular endothelial function in middle-aged and older (≥45 y) adults who do no perform regular aerobic exercise. In a double-blind, randomized, placebo-controlled crossover des...

What is the current status of trial NCT05872139?

This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2022-09-23. Estimated completion is 2023-05-01.

What conditions does trial NCT05872139 study?

This clinical trial studies the following conditions: Aging, Endothelial Dysfunction, Arterial Stiffness, Cardiovascular Function.

What interventions are being tested in trial NCT05872139?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Mitoquinone Mesylate (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05872139?

This trial is sponsored by Ball State University, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05872139 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aging

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05872139's enrollment target sits among peer trials

23 224th of 262 higher than 38 of 262 other Aging trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05872139, the US trial registry maintained by the National Library of Medicine. NCT05872139 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.